Search
More than 3,000 skin checks have been undertaken as part of a large clinical trial in WA’s Kimberley region aimed at halving the burden of skin sores in school-aged Aboriginal children.
Australia’s first national guideline for supporting the learning, participation and wellbeing of autistic children and their families.
Cystic fibrosis (CF) researchers are working hard to progress phage therapy as an alternative treatment to antibiotics in people with CF who develop life-threatening lung infections.
New research has revealed the extraordinary impact of a collaborative project between The Kids Research Institute Australia and the Papua New Guinea Institute of Medical Research, with rates of hospitalisation for pneumonia dropping by nearly 60 per cent thanks to the introduction of the pneumococcal vaccine
Patricia Ilchuk can still recall the day in August 2020 when her daughter Manna – then five weeks old – had her first seizure.
A The Kids Research Institute Australia study has found the average six-month-old Australian baby has more than one hour of screen time each day.
Researchers have made a world-first discovery on how to prevent severe respiratory infections in babies.
When Perth mum Lacy Swan’s daughter Charlotte failed the newborn hearing test at 3 days of age, the medical team explained it could simply be due to fluid on the ears.
Research
Rethinking a hybrid malaria chemoprevention delivery strategy for children in sub-perennial settings: a modelling study integrating age- and seasonally-targeted deliveryThe World Health Organization recommends perennial malaria chemoprevention (PMC), generally using sulfadoxine-pyrimethamine (SP) to children at high risk of severe Plasmodium falciparum malaria. Currently, PMC is given up to age two in perennial transmission settings. However, no recommendation exists for perennial settings with seasonal variation in transmission intensity, recently categorized as 'sub-perennial'.
Research
Value profile for Malaria vaccines and monoclonal antibodies1Malaria remains a leading cause of morbidity and mortality and is responsible for over 0.5 million annual deaths globally. During the first two decades of this century, scale-up of a range of tools was associated with significant reductions in malaria mortality in the primary risk group, young African children.